UK’s Drug Discovery Prospective at Risk, Warns Industry Body
According to a report commissioned by the Association of the British Pharmaceutical Industry (ABPI), the membership organization for UK drug manufacturers, Drug manufacturers in the UK are progressively more working in corporation to develop new medicines as companies move away from the traditional model of in-house research and development.
According to report, ‘The changing UK drug discovery landscape’, published on 17 October 60% of large biopharmaceutical companies have improved their investment in outsourcing and mutual working with other companies across the sector over the past decade so working with academic circles, medical research charities and bio-tech companies is showing considerable results such as manufacturing new drugs, including immune therapies for the treatment of cancer and others for Alzheimer’s disease.
The report’s findings were based on the results of a survey of 70 organizations as well as interviews with senior drug discovery experts.
But at the same time UK’s drug discovery potential is at risk from competition overseas, where more money is being spent on research and development sector because many organizations generally large firms reported a larger boost in their worldwide discovery investment than that in the UK.
UK needs to consider how it can best uphold its position as a central player in a vibrant international discovery landscape.